Kyverna Therapeutics Inc. (NASDAQ: KYTX)
$10.30
-0.7700 ( -6.96% ) 223.5K
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
Market Data
Open
$10.30
Previous close
$11.07
Volume
223.5K
Market cap
$445.81M
Day range
$10.12 - $11.33
52 week range
$6.75 - $35.06
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
3 | Insider transactions | 2 | Feb 07, 2024 |
3 | Insider transactions | 2 | Feb 07, 2024 |
3 | Insider transactions | 1 | Feb 07, 2024 |
3 | Insider transactions | 2 | Feb 07, 2024 |
3 | Insider transactions | 2 | Feb 07, 2024 |
3 | Insider transactions | 2 | Feb 07, 2024 |
3 | Insider transactions | 2 | Feb 07, 2024 |
3 | Insider transactions | 2 | Feb 07, 2024 |
3 | Insider transactions | 2 | Feb 07, 2024 |
3 | Insider transactions | 2 | Feb 07, 2024 |